




***FIG. 1***




*FIG. 2A*




*FIG. 2B*




*FIG. 2C*




*FIG. 2D*



*FIG. 3A*



*FIG. 3B*



*FIG. 3C*

*FIG. 4C*

IL-9 PROLIFERATION

$[^3\text{H}]$  TDR INCORPORATION ( $\times 10^{-3}$ )

- CONTROL  $\triangleright$  H2.8(25)
- H2.8(3)  $\circ$  H2.8(25)
- $\triangle$  H2.8(12)

(125-PRO) IL-2 (mM)

*FIG. 4B*

*FIG. 4A*

IL-2 PROLIFERATION

$[^3\text{H}]$  TDR INCORPORATION ( $\times 10^{-3}$ )

- CONTROL  $\triangle$  19B11 + H2.9(10)
- 19B11(20)  $\square$  19B11 + H2.8(50)
- $\circ$  19B11 + H2.8(2)

(125-PRO) IL-2 (mM)

*FIG. 4A*

IL-9 PROLIFERATION

$[^3\text{H}]$  TDR INCORPORATION ( $\times 10^{-3}$ )

- CONTROL  $\triangleright$  H2.8(25)
- H2.8(3)  $\circ$  H2.8(25)
- $\triangle$  H2.8(12)

IL-9 ( $\mu/\text{ml}$ )

*FIG. 4C*

FIG. 4F




FIG. 4E







FIG. 4D






*FIG. 5A*




*FIG. 5B*



*FIG. 5C*

## INTERLEUKINE-2 RECEPTOR



**FIG. 6A**

*FIG. 6B*

IL-2 AND IP 130 SEQUENCE ( $\alpha$ -HELICES ARE BOXED)




FIG. 7C




FIG. 7B




FIG. 7A




FIG. 8B







FIG. 8A




*FIG. 8D*



*FIG. 8C*




*FIG. 9E*



*FIG. 9D*


	1	10	20	30	% HELIX (CIRCULAR DICHROISM)	MAIN MOLECULAR SPECIES	ACTIVITY
APTSSTIKKTKTQLQLEHILLDLQMLNGINN							
1		30			50% (150 @ 30µM) 35% (4µM)	TETRAMER (4M-8M, Kd=30-100µM) /OCTAMER	+++
10		30			22% (150 @ 30µM)	DIMER (1M-2M,Kd=0.2µM) /TETRAMER (2M-4M,Kd=100µM)	++
1		22			<2%	-	-
1		10			0%	DIMER (1M-2M,Kd=50µM) (2M-4M,Kd=1.4mM)	-
5		15			0%	DIMER (1M-2M,Kd=113µM)	-
10		20			0%	MONOMER	ND
20		20			<5%	MONOMER	+

FIG. 10



IP130


*FIG. 11A*




IP130

*FIG. 11B*


BLOT 4G10 (ANTI  
PHOSPHOTYROSINE)



F I G .12 A




IL-2 IP130 IL-2 + IP130



▲ ACTIVATED STATs

NO STIMULATION  
IL-2  
IP130  
IL-2 + IP130  
**F I G . 13**



IL-2 RECEPTOR AND ITS MAJOR SIGNAL TRANSDUCTION PATHWAY


MODEL OF TRANSDUCTION PATHWAY INDUCED BY gp130

FIG. 1A

NK CELLS ( $CD56^+$ ) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION  
 (SYNERGY WITH IL-2)

TREATMENT	J31	J32	J33
IL-2 50 nM	14	12	14
IP130 60 $\mu$ M	0	17	$\leq 5$
IP130 120 $\mu$ M	0	14	<5
IL-2 50 nM + IP130 60 $\mu$ M	26	21	7
IL-2 50 nM + IP130 120 $\mu$ M	28	28	28


*FIG. 15*



EFFECTOR/TARGET = 10

STIMULATION  
3 DAYS

STIMULATION  
3 DAYS




EFFECTOR/TARGET = 10

FIG. 16A


FIG. 16B

*FIG. 16D*




*FIG. 16C*

STIMULATION  
9 DAYS



EFFECTOR/TARGET = 10

STIMULATION  
9 DAYS



○ MEDIUM    □ IP130  
● IL-2       ■ IL-2 + IP130

FIG. 16E

FIG. 16F




FIGURE 17




FIGURE 18




FIGURE 19